Cancer therapy continues to be key innovation area for us. We are interested in newly identified cancer targets, antibodies and other novel approaches to provided enhance immuno-oncology treatment.
Dysregulation of the microbiome can lead to a broad range of diseases. We are interested in functionally directed natural microbiome strains and mechanistically defined molecules that we can exploit through oral-based drugs and biotherapy products.
We are interested in innovations that will lead to products and therapies that can prevent neurological degeneration or regenerate neuronal activity to treat all forms of dementia, stroke, and traumatic brain injury and spinal injury.
Targeted approaches to induce tolerance to re-stablished immune system homoeostasis is a key innovation area for us. These include various modalities, platforms and administration routes.
We are interested in novel targets that will lead to products that can prevent prevent or reduce inflammation, especially for lung and skin fibrosis, liver and neurological inflammation
New vaccines and therapeutic approaches to prevent infectious disease. We are especially interested in new delivery approaches and adjuvants to strengthen fight against existing pathogens and prevent future pandemics.